Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-Ku, Tokyo, 105-8461, Japan.
Division of Nephrology, Department of Internal Medicine, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan.
Sci Rep. 2023 Oct 27;13(1):18455. doi: 10.1038/s41598-023-45514-4.
Efficacy of systemic corticosteroid therapy (CS) for long-term kidney survival in patients with IgA nephropathy (IgAN) is controversial. Therefore, prospective studies evaluating targeted therapies to lymphatic tissues in mucosal immune system responsible for production of nephritogenic IgA have been desired worldwide. Here, we aimed to evaluate the associations of CS and combination therapy of CS and tonsillectomy (CS + Tx) with kidney survival, using database from a nationwide multicenter prospective cohort study on IgAN. Primary outcome was a 50% increase in serum creatinine from baseline or dialysis induction. The analysis included 941 patients (CS/CS + Tx/non-CS 239/364/338), 85 (9.0%) of whom reached outcomes during median follow-up of 5.5 (interquartile range 2.0-8.0) years. On overlap weighting analysis with balanced baseline characteristics, CS and CS + Tx were associated with lower risk of kidney events when compared with non-CS (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.29-0.88 and HR 0.20, 95%CI 0.09-0.44, respectively). Notably, when compared with the CS, CS + Tx was associated with a lower risk of kidney events (HR 0.40, 95%CI 0.18-0.91). Present study demonstrated, keeping with favorable association of systemic CS with kidney survival, concurrent tonsillectomy as one of targeted interventions to lymphatic tissues may provide additional improvement to kidney survival in patients with IgAN.
全身皮质类固醇治疗 (CS) 对 IgA 肾病 (IgAN) 患者长期肾脏生存的疗效存在争议。因此,全世界都期望开展评估针对黏膜免疫系统淋巴组织的靶向治疗的前瞻性研究,这些淋巴组织负责产生致肾炎 IgA。在这里,我们旨在通过 IgAN 的全国多中心前瞻性队列研究的数据库,评估 CS 以及 CS 联合扁桃体切除术 (CS + Tx) 与肾脏生存的相关性。主要结局是血清肌酐从基线或透析诱导时增加 50%。该分析包括 941 名患者(CS/CS + Tx/非 CS 239/364/338),其中 85 名(9.0%)在中位随访 5.5 年(四分位距 2.0-8.0)期间达到结局。在具有平衡基线特征的重叠加权分析中,与非 CS 相比,CS 和 CS + Tx 与较低的肾脏事件风险相关(风险比 [HR] 0.51,95%置信区间 [CI] 0.29-0.88 和 HR 0.20,95%CI 0.09-0.44)。值得注意的是,与 CS 相比,CS + Tx 与较低的肾脏事件风险相关(HR 0.40,95%CI 0.18-0.91)。本研究表明,与全身 CS 与肾脏生存的有利相关性一致,扁桃体切除术作为淋巴组织的靶向干预之一,可能为 IgAN 患者的肾脏生存提供额外的改善。